NovAliX Enters into Alliance with Kyowa Hakko Kirin
News Jan 14, 2013
NovAliX SAS has announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019